COMMUNIQUÉS West-GlobeNewswire

XORTX Highlights Achievements of 2023 and Preparation for Registration Clinical Trial
19/03/2024
CALGARY, Alberta, March 19, 2024 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (" XORTX " or the “ Company ”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANUA WKN: A3UNZ), a late-stage clinical pharmaceutical company focused [...]
Engage with Pluri's Talent: Exciting Conference Appearances Ahead
19/03/2024
HAIFA, Israel, March 19, 2024 (GLOBE NEWSWIRE) -- Pluri Inc. (Nasdaq:PLUR) (TASE:PLUR) ("Pluri" or "the Company"), a leading biotechnology company that transforms cells into solutions that promote global wellbeing and [...]
Mendus to present NK cell program progress at the Innate Killer Summit
19/03/2024
Press Release Stockholm, Sweden, March 19, 2024 Mendus AB ("Mendus" publ; IMMU. ST), a biopharmaceutical company focused on immunotherapies targeting tumor recurrence, announces that it will present the progress of its [...]
IBA signs contract to install a Be-Efficient irradiation solution in Germany
19/03/2024
Louvain-la-Neuve, Belgium, March 19, 2024 – IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and electron beam and X-ray solutions for industrial irradiation, announced [...]
IBA signe un contrat pour l'installation d'une solution d'irradiation Be-Efficient en Allemagne
19/03/2024
Louvain-la-Neuve, Belgique, le 19 mars 2024 - IBA (Ion Beam Applications S.A.), le leader mondial des technologies d’accélération de particules et des solutions d'irradiation industrielle par faisceau d'électrons et [...]
AstriVax Rounds Out Executive Team with Chief Business Officer (CBO) Dr. Gregory Fanning
19/03/2024
Dr. Fanning brings a wealth of experience in creating infectious disease pipelines by internal R&D and licensing As the CBO of AstriVax, he will lead the company’s business development, including partnerships, [...]
ObsEva Announces Update on Board of Directors
19/03/2024
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – March 18, 2024 – ObsEva SA (SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies for women’s [...]
Madrigal Pharmaceuticals Announces Pricing of Upsized $600 Million Public Offering
19/03/2024
CONSHOHOCKEN, Pa., March 18, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for nonalcoholic steatohepatitis (NASH), today [...]
Merit Medical Systems to Announce First Quarter 2024 Results on April 30, 2024
18/03/2024
SOUTH JORDAN, Utah, March 18, 2024 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a leading global manufacturer and marketer of healthcare technology, announced today that it will release its financial [...]
Outlook Therapeutics® Announces Closing of Private Placement of up to $159 Million
18/03/2024
ISELIN, N.J., March 18, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to achieve the first approval for an ophthalmic formulation of bevacizumab for the [...]
QDOSE® Platform Partnership for Personalized Dosimetry in Radiopharmaceutical Therapy
18/03/2024
MELBOURNE, Australia and DRESDEN, Germany, March 19, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that it has entered into an agreement to commercially partner [...]
Arvinas Appoints Noah Berkowitz, M.D., Ph.D., as Chief Medical Officer
18/03/2024
- Awards Dr. Berkowitz an Inducement Grant in accordance with Nasdaq Listing Rule 5635(c)(4) - NEW HAVEN, Conn., March 18, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company [...]
Homology Medicines Declares Distribution to Common Stockholders
18/03/2024
BEDFORD, Mass., March 18, 2024 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX) today announced that it declared a distribution to its common stockholders of record as of the close of business on March 21, [...]
Aptose to Report Fourth Quarter and Year End 2023 Financial Results and Provide Corporate Update on Tuesday, March 26, 2024
18/03/2024
SAN DIEGO and TORONTO, March 18, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical- stage precision oncology company developing highly differentiated oral targeted agents to treat [...]
OBI Pharma annonce des présentations par affiches à la réunion annuelle de l’AACR 2024 pour OBI-992 et la plateforme CAM GlycOBI™
18/03/2024
Présentations par affiches pour mettre en lumière les dernières recherches sur OBI-992 (conjugué anticorps-médicament anti-TROP2) et la nouvelle plateforme de conjugué anticorps-médicament GlycOBI d’OBI TAIPEI, Taïwan, [...]
Avenue Therapeutics Reports Full Year 2023 Financial Results and Recent Corporate Highlights
18/03/2024
- Enrollment completed in Phase 1b/2a clinical trial of AJ201 for spinal and bulbar muscular atrophy; topline data expected in second quarter of 2024 - - Presented positive BAER-101 preclinical data at American Epilepsy [...]
Adverum Biotechnologies Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Pipeline Highlights and Corporate Updates
18/03/2024
- Preliminary LUNA data presented at the Annual Meeting of the Macula Society support potential best-in-class clinical activity and an encouraging safety profile in patients with wet AMD - - Completed $127.5 million [...]
QIAGEN partners with International Panel Physicians Association to increase awareness of tuberculosis screening requirements
18/03/2024
Joint educational initiative to focus on Interferon Gamma Release Assay (IGRA) benefits for healthcare providers // Updated U.S. CDC guidelines mandate IGRA testing for individuals aged 2 and older from high‑TB [...]
Tenaya Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
18/03/2024
Initial Data from Ongoing MyPeak™-1 Phase 1b of TN-201 for MYBPC3-associated HCM Expected in Second Half of 2024 On Track to Dose First Patient in RIDGE™-1Phase 1b Clinical Trial of TN-401 for PKP2-associated ARVC in [...]

Pages